Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and Pharmacokinetics of ONO-6414 in Healthy Volunteers and Patients With Active Ulcerative Colitis
NCT07749768Phase 1Recruiting
- Sponsor
- Ono Pharmaceutical
- Start
- Aug 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ONO-6414 in ulcerative colitis (UC) (3 arms), sponsored by Ono Pharmaceutical. Primary endpoints: Number of Participants with Adverse Events at 168 hours, Maximum Plasma Concentration of ONO-6414 at 72 hours and 3 more. Started Aug 2026; status: recruiting.
02
Drugs
ONO-6414
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT07749768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07749768.